Summit Therapeutics (NASDAQ:SMMT) is gearing up to announce its quarterly earnings on Monday, 2025-10-20. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Summit Therapeutics will report an earnings per share (EPS) of $-0.08.
The announcement from Summit Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Historical Earnings Performance
In the previous earnings release, the company missed EPS by $0.04, leading to a 9.08% drop in the share price the following trading session.
Here's a look at Summit Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | -0.09 | -0.08 | -0.07 |
| EPS Actual | -0.12 | -0.07 | -0.07 | -0.05 |
| Price Change % | -9.00 | 13.00 | -4.00 | 0.00 |
Market Performance of Summit Therapeutics's Stock
Shares of Summit Therapeutics were trading at $21.97 as of October 16. Over the last 52-week period, shares are up 7.78%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Summit Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
